NLRP3 Modulators for Treating Interleukin 1β Diseases
Summary
USPTO granted patent US12599616B2 to Zydus Lifesciences Limited for novel substituted sulfonylurea and sulfoximineurea derivatives as NLRP3 modulators for treating interleukin 1β-mediated diseases and conditions. The patent contains 11 claims and 20+ CPC classifications spanning A61K, C07C, C07D, and A61P therapeutic categories.
What changed
USPTO issued patent grant US12599616B2 to Zydus Lifesciences Limited, covering novel substituted sulfonylurea and sulfoximineurea derivatives as NLRP3 (NOD-like receptor family pyrin domain containing 3) modulators. The granted claims cover pharmaceutical compositions and methods of use for treating diseases where interleukin 1β activity is implicated, including inflammatory conditions.
Pharmaceutical companies and drug manufacturers developing NLRP3-targeted anti-inflammatory or immunology therapeutics should be aware of this patent when planning R&D programs in this therapeutic space. The patent may affect freedom-to-operate analyses for competing compounds in the interleukin-1β modulation field. No immediate compliance obligations arise from this patent grant.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Subtituted sulfonylurea and sulfoximineurea derivatives
Grant US12599616B2 Kind: B2 Apr 14, 2026
Assignee
ZYDUS LIFESCIENCES LIMITED
Inventors
Rajiv Sharma, Sameer Agarwal
Abstract
The present invention relates to novel compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions in which interleukin 1β activity is implicated.
CPC Classifications
A61K 31/64 A61K 31/545 A61K 38/20 A61K 38/21 A61K 45/06 C07C 311/55 C07C 381/10 C07C 2601/02 C07C 2601/04 C07C 2601/08 C07C 2601/14 C07C 2603/10 C07D 211/58 C07D 295/084 C07D 295/13 C07D 309/14 C07D 335/02 C07D 295/088 A61P 29/00
Filing Date
2021-02-26
Application No.
17800261
Claims
11
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.